• Itraconazole: Optimizing Triazole Antifungal Workflows in Ca

  2026-07-31

  Itraconazole stands out as a triazole antifungal agent optimized for drug interaction and biofilm resistance studies, especially in Candida models. Explore advanced workflows, troubleshooting insights, and protocol parameters that elevate reproducibility and reveal new mechanistic intersections, powered by APExBIO’s research-grade standard.

• DiscoveryProbe Natural Product Library Plus: Redefining Natu

  2026-07-30

  Explore how the DiscoveryProbe Natural Product Library Plus empowers advanced natural product screening for drug discovery, with a focus on targeting novel antiparasitic enzymes. This article provides original, in-depth analysis on leveraging chemical diversity for robust HTS and practical insights informed by recent landmark research.

• Sulfo-NHS-LC-Biotin: Technical Guide for Surface Protein Lab

  2026-07-30

  Sulfo-NHS-LC-Biotin addresses the need for stable, covalent biotin labeling of extracellular primary amines, especially on cell surface proteins, without permeating cell membranes. It is unsuitable for intracellular or reversible biotinylation workflows, making it best suited for applications requiring selective and irreversible extracellular tagging.

• SB-3CT: Gelatinase Inhibitor Workflows for Tumor and CNS Res

  2026-07-29

  SB-3CT stands out as a potent, selective gelatinase inhibitor, uniquely supporting both cancer metastasis and neuroplasticity research. Its mechanism-based action and high specificity for MMP-2 and MMP-9 enable reliable interrogation of extracellular matrix biology in disease models where precision matters most.

• Pioglitazone (SKU B2117): Reliable PPARγ Agonist for Lab Ass

  2026-07-29

  This article provides scenario-driven, evidence-based guidance for leveraging Pioglitazone (SKU B2117) in cell viability, proliferation, and inflammation research. Drawing on validated protocols and recent literature, we address common experimental challenges and demonstrate how Pioglitazone from APExBIO supports robust, reproducible outcomes in mechanistic and translational settings.

• Transmission Dynamics of Carbapenemase Genes in CREC During

  2026-07-28

  This study characterizes the prevalence and mobility of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) from eight teaching hospitals in Guangdong during the COVID-19 pandemic. The findings reveal dominant plasmid-mediated blaNDM-1 transmission, high multidrug resistance, and highlight critical surveillance priorities for healthcare-associated Gram-negative resistance.

• Acetylcholine Chloride in Gut-Brain Axis Research Workflows

  2026-07-28

  Acetylcholine Chloride enables precise modeling of cholinergic signaling in gut-brain axis studies, advancing translational epilepsy research. Practical protocols, troubleshooting insights, and comparative data make APExBIO’s reagent a keystone for neuroscience and autonomic nervous system investigations.

• AZD3463 ALK/IGF1R Inhibitor: Transforming Neuroblastoma Rese

  2026-07-27

  AZD3463, a potent ALK/IGF1R inhibitor from APExBIO, enables robust inhibition of ALK-driven signaling and empowers advanced combination therapy studies in neuroblastoma. Discover actionable protocols, troubleshooting wisdom, and experimental optimizations that maximize reproducibility and translational value.

• 3-Deazaadenosine Hydrochloride: Precision in Methylation Pat

  2026-07-27

  3-Deazaadenosine hydrochloride enables precise dissection of methylation-dependent signaling in hepatic stellate cell activation and fibrosis. Its high selectivity, robust solubility, and quality documentation make it an optimal choice for workflows exploring methyltransferase inhibition, cell proliferation, and inflammation models.

• Mitochondrial Calcium Signaling Represses Ferroptosis via GP

  2026-07-26

  This study uncovers a mechanistic link between mitochondrial calcium uptake through the MCU and the repression of ferroptosis, mediated by acetyl-CoA-driven acetylation of GPX4. These findings expand our understanding of how mitochondrial metabolism intersects with regulated cell death and suggest new angles for targeting ferroptosis in cancer and organ injury models.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cel

  2026-07-25

  This study demonstrates that inhibiting ATM, a key DNA repair kinase, synergizes with fenofibrate—an FDA-approved metabolic modulator—to induce senescence in high grade serous ovarian cancer (HGSOC) cells. These findings suggest a novel combinatorial therapeutic strategy for HR-proficient HGSOC patients, who are typically resistant to current treatments.

• NFE2L1–UPS Activation by DDI2 Mitigates Ferroptosis Risk

  2026-07-24

  The reference study reveals that the DDI2-mediated activation of the NFE2L1–ubiquitin-proteasome system (UPS) protects cells from ferroptosis by restoring proteasomal activity. These insights clarify the feedback between protein homeostasis and regulated cell death, highlighting new intervention points for ferroptosis-related pathologies.

• Selective β1 Blockade Preserves Hematopoietic Regeneration P

  2026-07-24

  This study reveals that nonselective β-adrenergic blockers, but not β1-selective agents like metoprolol, impair hematopoietic recovery after hematopoietic cell transplantation (HCT) in mice and humans. The findings highlight the importance of receptor selectivity in designing posttransplantation protocols to optimize engraftment and patient outcomes.

• PD98059 in Translational Research: Beyond MEK Inhibition

  2026-07-23

  This thought-leadership article navigates the evolving role of PD98059 as a selective MEK inhibitor, integrating mechanistic insight, evidence-based protocol guidance, and strategic perspectives for translational researchers. Drawing from recent advances in leukemia differentiation and neuroprotection models, we explore how PD98059 not only modulates the MAPK/ERK pathway but also informs the design of next-generation experimental and therapeutic strategies. The discussion bridges foundational biology, protocol optimization, and the competitive context, culminating in a vision for unlocking the full translational potential of MEK inhibition.

• Caffeic Acid Phenethyl Ester: Advanced NF-κB Inhibition Work

  2026-07-23

  Caffeic Acid Phenethyl Ester (CAPE) delivers potent, selective NF-κB inhibition for dissecting neuroinflammatory and angiogenic pathways—making it an essential tool for mechanistic and translational research. Learn how to optimize CAPE assays, overcome solubility challenges, and leverage recent zebrafish neurodegeneration models for reproducible, high-impact data.

399 records 6/27 page Previous Next First page 上5页 678910 下5页 Last page